Abstract: The invention relates to a transdermal system that is characterized by a content in a phosphodiesterase IV inhibitor, especially (−) rolipram or (R)-(−)-5-(4-methoxyphenyl-3-propoxy)-5-methyl-2-oxazolidinone.

Abstract: A device for transdermal administration of active medicinal agents is based on the active medicinal agent dissolved to an extent of at least 50% in a nonflowable, physiologically acceptable gel, which latter is distributed in a microdisperse mode in a crosslinked silicone elastomer.

Abstract: A vaginal ring comprises a supporting ring 1 free of active agent. A layer 2, which contains an active agent such as a steroid, is applied on its outer rim, optionally in a continuous groove provided in the supporting ring. This layer, in turn, is coated with a layer 3 devoid of active ingredient. All components preferably comprise an LTV silicone elastomer. The ratio of the thickness of the layer 2, containing an active agent, to the layer 3, free of active agent, is about 5-50:1. As a result, a long-term and uniform release rate is achieved for the active agent.

Abstract: A composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, which comprises:(a) a major supporting vaginal ring consisting essentially of a physiologically acceptable synthetic resin and having at least a portion of the annular surface thereof adapted to mate with corresponding minor, medicament-containing vaginal ring segment; and(b) at least one minor, medicament-containing vaginal ring segment adapted to mate with the modified annular surface of said major supporting vaginal ring and consisting essentially of a safe and effective amount of a pharmaceutically active amount of a nonionic, lipophilic drug dissolved or uniformly suspended in an elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.

Abstract: A composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, which comprises:A. a major supporting vaginal ring consisting essentially of a physiologically acceptable synthetic resin and having at least a portion of the annular surface thereof adapted to mate with corresponding minor, medicament-containing vaginal ring segment; andB. at least one minor, medicament-containing vaginal ring segment adapted to mate with the modified annular surface of said major supporting vaginal ring and consisting essentially of a safe and effective amount of a pharmaceutically active amount of a nonionic, lipophilic drug dissolved or uniformly suspended in an elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.